Intracranial and subcortical volumes in adolescents with early‐onset psychosis: A multisite mega‐analysis from the ENIGMA consortium by Gurholt, T. P. et al.
              
City, University of London Institutional Repository
Citation: Gurholt, T. P., Lonning, V., Nerland, S., Jørgensen, K. N., Haukvik, U. K., Alloza, 
C., Arango, C., Barth, C., Bearden, C. E., Berk, M., Bohman, H., Dandash, O., Díaz Caneja, ‐
C. M., Edbom, C. T., Erp, T. G. M., Fett, A-K. ORCID: 0000-0003-0282-273X, Frangou, S., 
Goldstein, B. I., Grigorian, A., Jahanshad, N., James, A. C., Janssen, J., Johannessen, C., 
Karlsgodt, K. H., Kempton, M. J., Kochunov, P., Krabbendam, L., Kyriakopoulos, M., 
Lundberg, M., MacIntosh, B. J., Rund, B. R., Smelror, R. E., Sultan, A., Tamnes, C. K., 
Thomopoulos, S. I., Vajdi, A., Wedervang Resell, K., Myhre, A. M., Andreassen, O. A., ‐
Thompson, P. M. and Agartz, I. (2020). Intracranial and subcortical volumes in adolescents 
with early onset psychosis: A multisite mega analysis from the ENIGMA consortium. Human ‐ ‐
Brain Mapping, doi: 10.1002/hbm.25212 
This is the published version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/25025/
Link to published version: http://dx.doi.org/10.1002/hbm.25212
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
R E S E A R CH A R T I C L E
Intracranial and subcortical volumes in adolescents with early-
onset psychosis: A multisite mega-analysis from the ENIGMA
consortium
Tiril P. Gurholt1,2,3 | Vera Lonning2,3 | Stener Nerland2,3 | Kjetil N. Jørgensen2,3 |
Unn K. Haukvik1,4 | Clara Alloza5 | Celso Arango5,6 | Claudia Barth2 |
Carrie E. Bearden7,8 | Michael Berk9,10 | Hannes Bohman11,12,13 |
Orwa Dandash9 | Covadonga M. Díaz-Caneja5,6 | Carl T. Edbom11 |
Theo G. M. van Erp14,15 | Anne-Kathrin J. Fett16,17,18 | Sophia Frangou19 |
Benjamin I. Goldstein20,21 | Anahit Grigorian20 | Neda Jahanshad22 |
Anthony C. James23,24 | Joost Janssen5,6 | Cecilie Johannessen2 |
Katherine H. Karlsgodt8,25 | Matthew J. Kempton26 | Peter Kochunov27 |
Lydia Krabbendam18 | Marinos Kyriakopoulos28,29 | Mathias Lundberg11,12,13,30 |
Bradley J. MacIntosh31,32 | Bjørn Rishovd Rund33,34 | Runar E. Smelror2,3 |
Alysha Sultan19,35 | Christian K. Tamnes2,3,36 | Sophia I. Thomopoulos21 |
Ariana Vajdi7 | Kirsten Wedervang-Resell1 | Anne M. Myhre37,38 |
Ole A. Andreassen1,2 | Paul M. Thompson21 | Ingrid Agartz2,3,11 | For the ENIGMA-
EOP Working Group
1Norwegian Center for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
2Norwegian Center for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
4Department of Adult Mental Health, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
5Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM,
Madrid, Spain
6School of Medicine, Universidad Complutense, Madrid, Spain
7Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California
8Department of Psychology, UCLA, Los Angeles, California
9IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia
10Orygen Youth Health Research Center, The Florey Institute for Neuroscience and Department of Psychiatry, Parkville, Victoria, Australia
11Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Stockholm Region, Stockholm,
Sweden, Stockholm, Sweden
12Department of Neuroscience, Child and Adolescent Psychiatry, Uppsala University, Uppsala, Sweden
13Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
14Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California
15Center for the Neurobiology of Learning, University of California Irvine and Memory, Irvine, California
16Department of Psychology, City, University of London, London, UK
Received: 31 July 2020 Revised: 11 September 2020 Accepted: 13 September 2020
DOI: 10.1002/hbm.25212
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
Hum Brain Mapp. 2020;1–12. wileyonlinelibrary.com/journal/hbm 1
17Department of Psychosis Studies, IoPPN, London, UK
18Department of Clinical, Neuro and Developmental Psychology, VU Amsterdam, Amsterdam, Netherlands
19Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York
20Center for Youth Bipolar Disorder, Sunnybrook Health Science Center, Toronto, Ontario, Canada
21Department of Psychiatry and Pharmacology, University of Toronto, Canada
22Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del
Rey, California
23Department of Psychiatry, University of Oxford, Oxford, UK
24Oxford Health Foundation NHS Trust, Oxford, UK
25Department Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, California
26Department of Psychosis Studies, King's College London, London, UK
27Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland
28Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK
29National and Specialist Children's Inpatient Unit (Acorn Lodge), South London and Maudsley NHS Foundation Trust, Beckenham, UK
30The Department of Clinical Science and Education, KI SÖS, Stockholm, Sweden
31Hurvitz Brain Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
32Department of Medical Biophysics, University of Toronto, Ontario, Canada
33Department of Psychology, University of Oslo, Oslo, Norway
34Department of Research, Vestre Viken Hospital Trust, Drammen, Norway
35Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
36PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway
37Child and Adolescent Psychiatry Unit, Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
38Department of Psychiatric Research and Development, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
Correspondence
Tiril P. Gurholt, Oslo University Hospital,
P.O. Box 4956, Nydalen, 0424 Oslo, Norway.
Email: t.p.gurholt@medisin.uio.no
Ingrid Agartz, University of Oslo and
Diakonhjemmet Hospital. P.O. Box
85 Vinderen, 0319 Oslo, Norway.
Email: ingrid.agartz@medisin.uio.no
Funding information
Forskningsrådet om Hälsa, Arbetsliv och
Välfärd, Grant/Award Numbers: 2017-00949,
521-2014-3487; Helse Sør-Øst RHF, Grant/
Award Numbers: 2004-259, 2006-186,
2017112; Horizon 2020 Framework
Programme, Grant/Award Numbers: 115916,
777394; National Alliance for Research on
Schizophrenia and Depression, Grant/Award
Number: 24138; National Health and Medical
Research Council, Grant/Award Numbers:
1059660, APP1156072; National Institutes of
Health, Grant/Award Numbers: MH105808,
P50MH066286, R01EB015611,
R01MH101506, R01MH113619,
R01MH116147, R01MH117601,
S10OD023696, U54EB020403; Nederlandse
Organisatie voor Wetenschappelijk
Onderzoek, Grant/Award Numbers:
451-13-035, 453-11-005; Norges
Forskningsråd, Grant/Award Numbers:
2137000, 223273, 250358, 288083; Seventh
Framework Programme, Grant/Award
Numbers: FP7- HEALTH-
Abstract
Early-onset psychosis disorders are serious mental disorders arising before the age of
18 years. Here, we investigate the largest neuroimaging dataset, to date, of patients
with early-onset psychosis and healthy controls for differences in intracranial and
subcortical brain volumes. The sample included 263 patients with early-onset psycho-
sis (mean age: 16.4 ± 1.4 years, mean illness duration: 1.5 ± 1.4 years, 39.2% female)
and 359 healthy controls (mean age: 15.9 ± 1.7 years, 45.4% female) with magnetic
resonance imaging data, pooled from 11 clinical cohorts. Patients were diagnosed
with early-onset schizophrenia (n = 183), affective psychosis (n = 39), or other psy-
chotic disorders (n = 41). We used linear mixed-effects models to investigate differ-
ences in intracranial and subcortical volumes across the patient sample, diagnostic
subgroup and antipsychotic medication, relative to controls. We observed signifi-
cantly lower intracranial (Cohen's d = −0.39) and hippocampal (d = −0.25) volumes,
and higher caudate (d = 0.25) and pallidum (d = 0.24) volumes in patients relative to
controls. Intracranial volume was lower in both early-onset schizophrenia (d = −0.34)
and affective psychosis (d = −0.42), and early-onset schizophrenia showed lower hip-
pocampal (d = −0.24) and higher pallidum (d = 0.29) volumes. Patients who were cur-
rently treated with antipsychotic medication (n = 193) had significantly lower
intracranial volume (d = −0.42). The findings demonstrate a similar pattern of brain
alterations in early-onset psychosis as previously reported in adult psychosis, but with
notably low intracranial volume. The low intracranial volume suggests disrupted neu-
rodevelopment in adolescent early-onset psychosis.
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1 | INTRODUCTION
Early-onset psychosis (EOP) disorders, defined as psychotic disor-
ders with onset of the first psychotic episode before age 18 years,
affect 0.05–0.5% of the population (Boeing et al., 2007; Dalsgaard
et al., 2019; Gillberg, Wahlström, Forsman, Hellgren, &
Gillberg, 1986; Sikich, 2013), and have a heterogeneous clinical
presentation. They are debilitating mental disorders and constitute
one of the leading causes of lifetime disease burden for adoles-
cents (Gore et al., 2011). With the exception of some prior multi-
site studies (Arango et al., 2012; Fraguas, Díaz-Caneja, Pina-
Camacho, Janssen, & Arango, 2016; Reig et al., 2011), structural
brain magnetic resonance imaging (MRI) studies in EOP are limited
by small sample sizes and low statistical power, typically including
fewer than 50 patients. To overcome these limitations, the
Enhancing Neuro Imaging Genetics through Meta Analysis
(ENIGMA; http://enigma.ini.usc.edu) Early-onset Psychosis Work-
ing Group was established, and this first ENIGMA-EOP study of
intracranial and subcortical brain volumes includes data from
11 participating sites.
Prior studies of EOP have shown lower overall brain volume
(El-Sayed, 2010; Frazier et al., 1996a; Matsumoto et al., 2001), alter-
ations in cortical gray matter volume/thickness (Arango et al., 2012;
Janssen et al., 2012; Janssen et al., 2014; Reig et al., 2011;
Thormodsen et al., 2013), lower thalamus (Frazier et al., 1996a;
Janssen et al., 2012), and higher caudate, putamen, pallidum (Frazier
et al., 1996a) and ventricular volumes (Frazier, Giedd, Hamburger,
et al., 1996; Juuhl-Langseth et al., 2012; Pagsberg et al., 2007;
Sowell et al., 2000), compared to healthy controls. Large-scale
ENIGMA meta-analyses in adult schizophrenia (van Erp et al., 2016)
and bipolar disorder (Hibar et al., 2016) reported lower hippocampal,
amygdala and thalamus, and higher lateral ventricle volumes; and
additionally lower intracranial (ICV) and accumbens volumes, and
higher pallidum volume in schizophrenia (van Erp et al., 2016). These
volumetric differences were less marked in bipolar disorder than in
schizophrenia, a finding corroborated by a direct comparison study
(Rimol et al., 2010). In teenagers with childhood-onset schizophrenia,
one study have indicated similar magnitudes of subcortical volume dif-
ferences to that of adult schizophrenia (Frazier et al., 1996a). Yet, it is
still not clear how similar brain structural alterations in EOP are to
those of adult-onset psychosis, or to other neurodevelopmental disor-
ders such as autism spectrum disorder (ASD) and attention deficit
hyperactivity disorder (ADHD).
Only two EOP studies have investigated a comprehensive array
of subcortical structures (Frazier et al., 1996a; Juuhl-Langseth
et al., 2012). These reported higher caudate, lateral and fourth
ventricular volumes (Juuhl-Langseth et al., 2012), and higher caudate,
putamen and pallidum volumes that correlated with neuroleptic treat-
ment and age of onset (Frazier et al., 1996a). A study on early-onset
bipolar disorder, where 61% of patients had psychosis symptoms,
reported lower amygdala and higher putamen volumes (DelBello,
Zimmerman, Mills, Getz, & Strakowski, 2004). It has been difficult to
establish a consistent pattern of subcortical alterations in EOP from
these studies, due to the limited number of previous studies and their
relatively low sample sizes.
Antipsychotic treatment has been linked to basal ganglia volume
increases in adult patients (Chakos et al., 1994; Chua et al., 2009; di
Sero et al., 2019; Hashimoto et al., 2018; van Erp et al., 2016). Although
not consistently replicated (Emsley et al., 2015), this finding may reflect
striatal hypertrophy as a compensatory response to striatal dopamine
receptor antagonism (Chua et al., 2009), the main target of antipsy-
chotics, and a link between antipsychotic dose and basal ganglia volume
has been shown (Andersen et al., 2020; di Sero et al., 2019). This pro-
posed mechanism is likely mediated by the dopamine D2 receptor
(Guma et al., 2018), and the neurobiological responses may differ as a
function of neurodevelopmental phase (Moe, Medely, Reeks, Burne, &
Eyles, 2017). In patients with childhood-onset schizophrenia (i.e., onset
before age 13 years) investigated during adolescence, pallidum volumes
enlarged with neuroleptic exposure (Frazier et al., 1996a) while transfer
to clozapine treatment was associated with caudate volume reduction
(Frazier et al., 1996b). In early-onset schizophrenia (i.e., onset before age
18 years), antipsychotic medication use was associated with ventricular
enlargement but not with higher caudate volumes (Juuhl-Langseth
et al., 2012).
The aim of this study was to robustly identify differences in ICV
and subcortical volumes using a mega-analytical approach1 of the
hitherto largest neuroimaging sample of adolescent patients with EOP
and healthy controls. We performed subgroup analyses by dividing
patients into three groups: (a) early-onset schizophrenia, (b) affective
psychosis disorders, including bipolar and major depressive disorders
with psychotic features, and (c) other psychoses, including psychosis
not otherwise specified, and brief psychotic disorders. Based on prior
adult studies (Hibar et al., 2016; Rimol et al., 2010; van Erp
et al., 2016), we hypothesized lower ICV and volumetric subcortical
abnormalities in EOP similar to those of adult psychosis when com-
pared to healthy controls; with strongest effects in early-onset schizo-
phrenia, and an attenuated but similar pattern in affective psychosis
and other psychoses. Based on prior studies on antipsychotic treat-
ment (Chakos et al., 1994; Chua et al., 2009; di Sero et al., 2019;
Frazier et al., 1996a; Hashimoto et al., 2018; van Erp et al., 2016), we
expected antipsychotic medication use in EOP to be associated with
enlarged basal ganglia volumes.
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2 | MATERIALS AND METHODS
2.1 | Study samples
Eleven cohorts with MRI data acquired on 16 scanners (1.5T: four scan-
ners/223 scans; 3T: 12 scanners/399 scans) contributed to this study,
yielding a combined sample of 263 patients with EOP and 359 healthy
controls. The patient group included early-onset schizophrenia (n = 183),
affective psychosis (n = 39), or other psychosis (n = 41) according to
DSM-IV (American Psychiatric Association, 2000) or ICD-10 (World
Health Organization, 2004). Patients were between age 12 to 18 years at
scan (14 had illness onset before age 12). Table 1 presents demographic
and clinical information for the combined sample. Table S1 demonstrates
cohort-wise demographic and clinical information, and Table S2 cohort-
specific inclusion and exclusion criteria. Five sites shared positive and neg-
ative syndrome (PANSS; Kay, Fiszbein, & Opler, 1987) scores, while one
site shared Scale for the Assessment of Negative/Positive Symptoms
(SANS [Andreasen, 1983]/SAPS [Andreasen, 1984]) scores.
All participants, parents or legal guardians gave written informed
consent or assent as appropriate. Each site had ethical approval from
their local ethics committees or institutional review board to participate
in the study and share anonymized data for mega-analysis. The study
was conducted in accordance with the Helsinki Declaration.
2.2 | MR imaging acquisition and processing
T1-weighted brain images were processed locally at each site with
FreeSurfer (version 5.3.0; http://surfer.nmr.mgh.harvard.edu;
Fischl, 2012) following standardized ENIGMA processing protocols
(http://enigma.ini.usc.edu). See Table S3 for cohort/scanner-specific
acquisition parameters. In the statistical analyses, we included the
same brain measures as prior ENIGMA studies (Hibar et al., 2016; van
Erp et al., 2016), namely estimated ICV (Buckner et al., 2004) and
bilateral subcortical volumes: accumbens, amygdala, hippocampal,
thalamus, lateral ventricle, caudate, pallidum, and putamen.
The segmentation quality was assessed following a standardized
protocol by identifying outlier volumes at each site, which were
excluded if the segmentation was deemed inaccurate after visual
inspection (Note S1).
2.3 | Statistical analyses
The demographic variables of patients and controls were compared
using χ2-test for categorical variables and t-test/two-sided Wilcoxon
rank sum test for normally/non-normally distributed continuous vari-
ables. Normality was assessed using the Shapiro–Wilk test. We
TABLE 1 Demographic and clinical information
Patients (N = 263) Controls (N = 359) χ2-test/Wilcoxon rank-sum test p value
N (%) N (%)
Females 103 (39.2%) 163 (45.4%) 2.2 .1410
Mean ± SD Mean ± SD
Agea (years) 16.4 ± 1.4 15.9 ± 1.7 0.5 .0003
Age at onsetb (years) 15.0 ± 1.9
Duration of illnessb (years) 1.5 ± 1.4
PANSS positivec 18.9 ± 7.7
PANSS negativec 18.1 ± 7.6
Range (median) Range (median)
Age (years) 12–18.9 (16.7) 12–18.9 (16)
Age of onsetb (years) 7.6–18.2 (15.2)
Duration of illnessb (years) 0–7.5 (1.0)
PANSS positivec 7–46 (19)
PANSS negativec 7–43 (16)
N N
EOS/AFP/OTP 183/39/41
AP users/non-usersd 193/39
AP users EOS/AFP/OTPd 136/26/31
1.5T/3T 117/146 106/253
Note: p values < .05 considered significant.
Abbreviations: AFP, affective psychosis; AP, antipsychotics; EOS, early-onset schizophrenia; OTP, other psychoses; PANSS, positive and negative syn-
drome scale.
aNot normally distributed, applied Wilcoxon rank-sum test.
b32 had missing AAO/DOI.
c90 had missing PANSS positive/negative scores.
d31 (30 EOS, one AFP) had missing information on current AP medication.
4 GURHOLT ET AL.
evaluated the distribution of the participants age (Figure S1) and brain
volumes (Figure S2).
We investigated ICV and subcortical volumes mega-analytically
with linear-mixed effects (LME) models (Laird & Ware, 1982) using
the lme function (nlme package) in R (version 3.5.2; www.r-project.
org). We adjusted for age, sex, and ICV (subcortical volumes only) as
fixed-effects variables unless otherwise specified, and scanner as
random-effects variable. Independent analyses were conducted for
combined (averaged), and left/right hemispheric structures. We refer
to combined structures unless otherwise specified.
In the main model, we investigated patient-control differences in
ICV and subcortical volumes. For qualitative comparison of between-
cohort heterogeneity, we included a complementary meta-analysis
(Note S2). Follow-up analyses were performed for age-by-group or
sex-by-group interactions. Additionally, we conducted follow-up ana-
lyses of the main model without adjusting for ICV to explore the rela-
tive difference in subcortical structures.
Next, we conducted follow-up analyses of the main LME model for
patient characteristics on brain volumes. We stratified patients into early-
onset schizophrenia, affective psychosis, and other psychoses, and com-
pared each diagnostic subgroup to controls. Similarly, we stratified
patients into current antipsychotic users and current non-users, and com-
pared them to controls. Finally, in patients, we tested for effects of age at
onset, duration of illness, and antipsychotic medication users versus non-
users, on brain volumes. These analyses were adjusted for age, sex, and
ICV as fixed-effects variables and scanner as random-effects variable.
We computed the Cohen's d effect sizes from the t-statistics for
categorical variables and via the partial correlation coefficient (r) for
continuous variables (Nakagawa & Cuthill, 2007). We corrected for
multiple comparisons using the false discovery rate (FDR; Benjamini &
Hochberg, 1995) with α = 0.05 and computed a study-wide FDR
threshold across N = (9 + 2*8)*(8 + 2) + (9 + 8*2)*3 = 325 tests, which
is the number of reported combined, left- and right-hemisphere tests,
leading us to consider p values ≤.0062 as significant. Nominally signifi-
cant p values (p ≤ .05) are reported. We report uncorrected p values.
Tables S4–S15 present the results of the individual analyses.
3 | RESULTS
3.1 | Demographics and clinical information
Patients with EOP were significantly older than controls (Δ = 0.5,
p = 3 × 10−4). The largest patient group was early-onset schizophrenia
(69.5%), followed by other psychoses (15.6%), and affective psychosis
(14.8%). The patients had mean illness duration 1.5 ± 1.4 years, age at
onset 15.0 ± 1.9 years, and PANSS positive and negative scores of
18.9 ± 7.7 and 18.1 ± 7.6, respectively. 193 (73.4%) patients received
current treatment with antipsychotic medication (Table 1). Split by
diagnosis, 136 (74.3%) early-onset schizophrenia, 31 (75.6%) other
psychosis, and 26 (66.7%) affective psychosis patients currently used
antipsychotic medication.
3.2 | Case–control differences
EOP had significantly lower ICV (Cohen's d = −0.39, p = 3 × 10−6) and
hippocampal volume (d = −0.25, p = .003), higher caudate (d = 0.25,
p = .002), and pallidum (d = 0.24, p = .004) volumes, and nominally sig-
nificant lower amygdala (d = −0.2, p = .020), and higher lateral ventric-
ular (d = 0.22, p = .010) volumes, compared to controls (Figure 1).
In split-hemisphere analyses, only structures of the left hemi-
sphere were significantly altered, showing lower hippocampal
(d = −0.24, p = .005), and higher caudate (d = 0.27, p = .001), pallidum
(d = 0.28, p = 8e-04), and lateral ventricular (d = 0.24, p = .004) vol-
umes (Table S4).
Follow-up analyses did not show significant age-by-group or sex-
by-group interactions (Tables S5 and S6).
In follow-up analyses unadjusted for ICV, we observed signifi-
cantly lower hippocampal (d = −0.42, p = 6 × 10−7), amygdala
(d = −0.32, p = 2 × 10−4), thalamus (d = −0.32, p = 1 × 10−4), and
accumbens (d = −0.25, p = .004) volumes in EOP relative to controls
(Figure S3). Effects were similar bilaterally (Table S7).
The complementary meta-analysis of patient-control differences
largely corroborated the results, but additionally showed significantly
higher lateral ventricular volume (d = 0.3, p = 5 × 10−4), with similar
effects bilaterally (Table S8). Forest plots illustrate the variability
among cohorts (Figures S4–S6).
3.3 | Diagnostic subgroups
When stratifying by EOP diagnostic subgroups, both early-onset
schizophrenia (d = −0.34, p = 1 × 10−4) and affective psychosis
(d = −0.42, p = .003) showed lower ICV, while only early-onset schizo-
phrenia showed significantly lower hippocampal (d = −0.24, p = .006)
and higher pallidum (d = 0.29, p = 9 × 10−4) volumes relative to con-
trols. There were nominally significant differences for amygdala
(schizophrenia: d = −0.19, p = .029; affective psychosis: d = −0.31,
p = .026), thalamus (schizophrenia: d = −0.19, p = .031), accumbens
(affective psychosis: d = −0.29, p = .041), caudate (schizophrenia:
d = 0.19, p = .029; other psychosis: d = 0.31, p = .024), and lateral ven-
tricle (affective psychosis: d = 0.32, p = .024; other psychosis:
d = 0.27, p = .048; Figure 2, Table S9) volumes. In split-hemisphere
analyses, early-onset schizophrenia showed significantly lower hippo-
campal (left: d = −0.23, p = .008) and higher pallidum (left: d = 0.28,
p = .001; right: d = 0.24, p = .006) volumes, while affective psychosis
showed lower left accumbens (d = −0.39, p = .005) volume
(Tables S10 and S11).
3.4 | Age at onset and illness duration
There were no significant effects of age at onset or duration of ill-
ness on the included regional brain volumes in EOP (Tables S12
and S13).
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3.5 | Antipsychotic medication
When stratifying patients based on current antipsychotic medication
use, users (n = 193) had significantly lower ICV (d = −0.42,
p = 2 × 10−6), and nominally significant lower hippocampal, and higher
caudate, pallidum, and lateral ventricular volumes relative to controls
(Figure 3, Table S14). In split-hemisphere analyses, antipsychotic users
showed significantly higher left caudate (d = 0.24, p = .006) and palli-
dum (d = 0.26, p = .003) volumes compared to controls. Non-users
(n = 39) showed nominally significant lower hippocampal volume.
Direct comparison between antipsychotic users/non-users
showed no significant volumetric differences (Table S15).
4 | DISCUSSION
In this mega-analysis, we found a structural brain signature character-
ized by significantly lower ICV and hippocampal volumes, and higher
caudate and pallidum volumes in EOP compared to healthy controls.
Lower ICV featured in both early-onset schizophrenia and affective
F IGURE 1 Regional brain volumes in early-onset psychosis compared to healthy controls. Notes: Linear mixed-effects models applied for
diagnostic differences between patients with early-onset psychosis and healthy controls (reference), adjusted for age, sex, and ICV (for subcortical
structures) as fixed-effects variables and scanner as a random-effects variable. Error bars show pooled effect size ± standard error. Significant
differences indicated by *
F IGURE 2 Regional brain volumes in early-onset psychosis patient subgroups compared to healthy controls. Notes: Linear mixed-effects
models applied for diagnostic differences in patient subgroups (EOS/AFP/OTP) with controls (reference), adjusted for age, sex, and ICV (for
subcortical structures) as fixed-effects variables and scanner as a random-effects variable. Error bars show mean effect size ± standard error.
Significant differences indicated by *. AFP, affective psychosis; EOS, early-onset schizophrenia; OTP, other psychoses
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psychosis, while lower hippocampal and higher pallidum volumes were
limited to schizophrenia. Enlarged left caudate and pallidum volumes
were observed in patients currently on antipsychotic treatment.
The most striking finding was the lower ICV in patients with EOP
(d = −0.39). This effect was larger than the lower ICV reported in a
meta-analysis of adult schizophrenia (d = −0.12; van Erp et al., 2016),
and no such effect was reported for adult bipolar disorders (Hibar
et al., 2016) (Figure 4a). ICV expands rapidly in early age, driven by
brain growth, and is thought to reach 90% of its final volume by early
adolescence (Courchesne et al., 2000; Haijma et al., 2013). A study
combining multiple longitudinal samples found evidence for continued
ICV expansion, with an estimated annual increase of 1% from late
childhood to mid-adolescence, with stabilization in late adolescence
(Mills et al., 2016). Given the relative stability of ICV from mid-
adolescence onwards, our findings of lower ICV in EOP suggest an
aberrant neurodevelopment, which is more severe and/or established
earlier than in adult-onset psychosis.
Interestingly, a prior multisite study found lower ICV in ADHD
(d = −0.10), with strongest effects among children (d = −0.14) and
adolescents (d = −0.13; not significant; Hoogman et al., 2017), which
is smaller than the effect size observed in EOP (d = −0.39; Figure 4b).
In contrast, higher ICV was reported in ASD (d = 0.13; van Rooij
et al., 2018), indicating differential neurodevelopmental mechanisms.
Our findings further highlight the importance of considering ICV in
imaging studies of neurodevelopmental disorders, and suggest the
need for research into early mechanisms influencing smaller head
development, including longitudinal studies and normative modeling
(Wolfers et al., 2018) of growth patterns from birth, and their relation-
ship to cognitive development and functioning.
The subcortical signature of EOP appeared similar to that of adult
schizophrenia (van Erp et al., 2016) and bipolar disorder (Hibar
et al., 2016) relative to controls (Figure 4a). Similarities included lower hip-
pocampal, and higher pallidum (schizophrenia only) and lateral ventricular
(nominally significant in EOP) volumes; except for pallidum, effect sizes
were less pronounced than in schizophrenia. Additionally, we confirmed
the higher caudate volumes, as previously observed in EOP (Frazier
et al., 1996b; Juuhl-Langseth et al., 2012). Generally, the magnitude of
subcortical differences in EOP relative to controls appeared greater than
those reported in the ADHD (Hoogman et al., 2017) or ASD (van Rooij
et al., 2018) samples, and the directionality of effects were similar for lim-
bic structures, while opposing for basal ganglia structures (Figure 4b).
The hippocampus showed the lowest volume in EOP relative to
controls, in agreement with findings in adult schizophrenia (van Erp
et al., 2016) and bipolar disorder (Hibar et al., 2016). The effect size
(d = −0.25) was similar to those reported in bipolar disorder
(d = −0.23; Hibar et al., 2016), but smaller than in schizophrenia
(d = −0.46; van Erp et al., 2016). Lower hippocampal volume was also
reported in children (d = −0.12; <15 years) and adolescents
(d = −0.24; age-range 15–21 years) with ADHD (Hoogman
et al., 2017). Thus, lower hippocampal volume features across several
neurodevelopmental disorders, and may reflect both shared and dis-
tinct illness mechanisms. Adult studies have shown hippocampal sub-
field alterations in schizophrenia and bipolar disorder (Haukvik et al.,
submitted 2020; Haukvik, Tamnes, Söderman, & Agartz, 2018). Future
EOP studies should track volumetric change across the illness course
and perform fine-scale mapping to advance our understanding of both
the timing and location of hippocampal disruption in neu-
rodevelopmental disorders.
F IGURE 3 Regional brain volumes by current antipsychotic medication status in early-onset psychosis compared to healthy controls. Notes:
Linear mixed-effects models investigating the effect of antipsychotic medication user/non-user with controls (reference), adjusted for age, sex,
and ICV (for subcortical structures) as fixed-effects variables and scanner as a random-effects variable. Error bars show mean effect size
± standard error. Significant differences indicated by *
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Our finding of lateral ventricular enlargement in EOP (nominally
significant combined structure, significant left hemisphere) cor-
responded closely with the adult literature, but showed a smaller
effect size than reported for both adult schizophrenia (van Erp
et al., 2016) and bipolar disorder (Hibar et al., 2016). Prior studies indi-
cate progressive ventricular expansion across the illness course
(Kempton, Stahl, Williams, & DeLisi, 2010). Thus, the short illness
duration of patients with EOP could explain the smaller effect size,
but longitudinal studies are needed to examine this possibility.
In contrast to studies on adult schizophrenia (van Erp
et al., 2016), we did not detect significantly lower amygdala, thalamus
and accumbens, or higher putamen volumes. However, we observed
trends in the same direction and therefore cannot rule out that the
smaller sample size or short duration of illness could explain some of
these differences. Further, when omitting ICV as a fixed-effects vari-
able, these volumes (except putamen) were significantly lower than in
controls. Since EOP shows larger effect sizes for ICV than for adult
schizophrenia (van Erp et al., 2016), adjusting for ICV may partly
explain the difference in results. This suggests that the relative differ-
ence for amygdala, thalamus and accumbens volumes is larger in EOP
versus adolescent controls, than for adult schizophrenia.
In the subgroup analyses, we observed lower ICV in both early-
onset schizophrenia and affective psychosis. Significantly lower hip-
pocampal and higher pallidum volumes were limited to early-onset
schizophrenia, while lower left accumbens was observed in affective
psychosis. Since most patients had a diagnosis of early-onset
F IGURE 4 Effect sizes observed in early-onset psychosis compared to other neurodevelopmental disorders from prior ENIGMA publications.
Notes: Figure compares the effect sizes that we observe in EOP with those from prior ENIGMA publications; In (a) meta-analysis of adult
schizophrenia (van Erp et al., 2016) and bipolar disorder (Hibar et al., 2016), and in (b) mega-analyses of life-span ADHD (Hoogman et al., 2017)
and ASD (van Rooij et al., 2018). The age-ranges and healthy control populations differs among the studies, and the ADHD study did not report
on the lateral ventricles. ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; EOP, early-onset
psychosis; SZ, schizophrenia
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schizophrenia, the subgroup differences may be explained by the
unbalanced sizes of the subgroups. Indeed, comparable effect sizes
were observed for hippocampal volume in early-onset schizophrenia
(d = −0.24; n = 183) and affective psychosis (d = −0.23; n = 39);
although not significant in affective psychosis. The supplementary
meta-analysis suggests a great degree of heterogeneity across the
included samples, which could reflect differences in inclusion and
exclusion procedures and criteria, or subgroup differences, resulting in
variable representation. This further highlights the necessity for large
samples when characterizing heterogeneous disorders composed of
clinically diverse subgroups.
Our findings of significantly enlarged left pallidum and caudate
volumes, and trends towards enlarged putamen volumes in antipsy-
chotic medicated patients suggest similar medication effects on brain
structure in adolescents and adults. Intriguingly, the significantly
higher caudate volume seen in EOP was not observed in adult schizo-
phrenia (van Erp et al., 2016) or bipolar disorder (Hibar et al., 2016). In
past meta-analyses of schizophrenia (Haijma et al., 2013; Keshavan
et al., 1994), lower caudate volumes were seen in antipsychotic-naive
patients but not in medicated patients. We did not find lower caudate
volume in non-medicated patients compared to controls, which may
point to a relative conservation of caudate volume in early-onset com-
pared to adult-onset psychosis. However, the proportion of patients
not using antipsychotics was low; therefore, the comparisons
between users and non-users may have been underpowered. Further-
more, we could not ascertain that the non-medicated patients were
naïve to previous antipsychotic medication. In a previous study of
early-onset schizophrenia, the enlarged caudate volumes were not
linked to antipsychotic medication use (Juuhl-Langseth et al., 2012),
while in adolescents with childhood-onset schizophrenia who initially
were on typical neuroleptics, caudate enlargement declined following
clozapine treatment (Frazier et al., 1996b).
This study had some limitations. The cross-sectional design pre-
cluded the investigation of developmental trajectories. Data was col-
lected from different sites, and site-wise differences in diagnostic
routines and MRI acquisition may influence the results. ICV and height
show genetic correlation (Adams et al., 2016). We did not have infor-
mation on height/weight, and could not test whether small body size
explained the ICV differences. The validity of the FreeSurfer esti-
mated ICV has been questioned (Heinen et al., 2016; Klasson, Olsson,
Eckerström, Malmgren, & Wallin, 2018), and it is an indirect measure-
ment of the intracranial volume. In the medication analysis, we did not
adjust for patient subgroup or illness severity that may influence the
results. We could not ascertain possible prior antipsychotic use in cur-
rent non-users, nor putative effects of cumulative antipsychotic expo-
sure, antipsychotic type and dosage, age at initial treatment, or the
effects of lithium and other mood stabilizers.
Strengths of this study include the hitherto largest adolescent
EOP sample, harmonized and validated ENIGMA MRI processing pro-
tocols, and a mega-analytical approach previously shown to be more
sensitive than meta-analysis (Boedhoe et al., 2019). The standardized
analysis pipeline enabled comparative discussion with results from
prior ENIGMA studies. Patients with EOP likely have shorter illness
duration, less treatment exposure, shorter history of adverse lifestyle,
and less alcohol/substance use, compared to adult patients. Thus, the
influence of these confounding variables should be comparably
smaller than in adult samples.
5 | CONCLUSION
The pattern of volumetric differences in EOP overlapped with, but
also showed notable deviations from findings as previously demon-
strated in adult psychosis studies. Particularly, the large effect size for
ICV may point to a greater involvement of neurodevelopmental mech-
anisms in EOP, possibly serving as a predictor for early psychosis risk.
Future studies should investigate the biological mechanisms of low
ICV to identify potential risk markers and targets for differential psy-
chiatric treatment in EOP. This study illustrates the benefits of large-
scale international collaborative efforts in characterizing brain struc-
tural abnormalities in rare disorders and lays the groundwork for
future studies of the neural foundations for EOP.
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ENDNOTE
1 A meta-analysis aggregates summary results (e.g., effect size estimates
and confidence intervals) across studies, while a mega-analysis aggre-
gates individual participant data across cohorts. For an empirical compar-
ison of the two techniques using structural MRI data, see Boedhoe
et al. (2019).
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